Systemic chemotherapy for malignant melanoma

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Malignant melanoma is highly resistant to conventional chemotherapy, with response rates around 20% for standard single agents.
• Adjuvant therapies have not proven effective for post-surgical treatment of primary or regional lymph node disease.
• Combinations of chemotherapy drugs have not demonstrated superiority over single agents in treating melanoma.

Purpose of the Study:

• To review the current landscape of chemotherapy for malignant melanoma.
• To explore novel strategies for overcoming chemoresistance in melanoma.
• To provide guidance on treatment approaches for metastatic melanoma.

Main Methods:

• Literature review of studies on chemotherapy agents and treatment strategies for malignant melanoma.
• Analysis of response rates and long-term outcomes for various therapeutic interventions.
• Discussion of emerging strategies, including biological response modifiers and drug resistance mechanisms.

Main Results:

• Standard single agents like dacarbazine and nitrosoureas yield response rates of approximately 20%, with occasional long-term remissions.
• Newer agents such as cisplatin and fotemustine show activity.
• High-dose alkylating agents and isolated limb perfusion suggest resistance is not absolute, pointing to glutathione modulation as a potential strategy.

Conclusions:

• While chemotherapy resistance is a major challenge in malignant melanoma, strategies like glutathione modulation offer potential for improved efficacy.
• Observation without treatment is a valid approach for asymptomatic metastatic melanoma patients.
• Single-agent dacarbazine or lomustine are reasonable choices for chemotherapy outside of clinical trials.